Oxford BioMedica PLC

Oxford BioMedica plc is a contract development and manufacturing organization focused on delivering therapies to patients worldwide. Its LentiVector platform is a lentiviral vector-based gene delivery system designed to overcome safety and delivery issues of earlier vector generations. It also offers InAAVate, a proprietary dual-plasmid system for transient transfection, and a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies, providing viral vector development and manufacturing services for lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. It was formerly known as Pinco 838 Limited and changed its name to Oxford BioMedica plc in October 1996. Incorporated in 1996, it is headquartered in Oxford, the United Kingdom.